EGX disclosure regarding Rameda’s manufacturing of “Anviziram” Tablets the Generic Equivalent of Japanese antiviral Avigan for treatment of Covid-19 patients and receives approval from Egyptian Drug Authority to manufacture Remedsivir Regulatory DisclosuresBy adminJune 22, 2020
EGX disclosure regarding the upcoming AGM on 10 May 2020 Regulatory DisclosuresBy adminApril 15, 2020
EGX disclosure announcing the acquisition of a generic anti-inflammatory analgesic molecule Regulatory DisclosuresBy adminApril 1, 2020